aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.08−0.91 (-18.24%)
Close on Nov 18, 2026Market cap $400.20MP/E –Yield –
aTYR PHARMA operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
aTYR PHARMA's operating income for the twelve months ending Jun 30, 2026 was -$63.86M. For fiscal 2025 it was -$77.63M. The highest annual figure on record is -$15.91M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$77.63M | – |
| FY2024 | Dec 31, 2024 | -$67.91M | – |
| FY2023 | Dec 31, 2023 | -$54.92M | – |
| FY2022 | Dec 31, 2022 | -$46.40M | – |
| FY2021 | Dec 31, 2021 | -$34.02M | – |
| FY2020 | Dec 31, 2020 | -$15.91M | – |
| FY2019 | Dec 31, 2019 | -$22.98M | – |
| FY2018 | Dec 31, 2018 | -$32.82M | – |
| FY2017 | Dec 31, 2017 | -$47.15M | – |
| FY2016 | Dec 31, 2016 | -$57.94M | – |
| FY2015 | Dec 31, 2015 | -$47.62M | – |
| FY2014 | Dec 31, 2014 | -$23.55M | – |
| FY2013 | Dec 31, 2013 | -$19.54M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.75M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.64M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.64M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.45M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.20M | -487.4% |
| Q4 FY2020 | Dec 31, 2020 | -$4.94M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.51M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.32M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.88M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.96M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.68M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.96M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.22M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.20M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.83M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.91M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.21M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.53M | – |
| Q3 FY2016 | Sep 30, 2016 | -$13.87M | – |
See a number that looks wrong?